Research Techniques Made Simple: Molecular Docking in Dermatology - A Foray into In Silico Drug Discovery

Research output: Contribution to journalShort survey

Abstract

Drug discovery is a complex process with many potential pitfalls. To go to market, a drug must undergo extensive preclinical optimization followed by clinical trials to establish its efficacy and minimize toxicity and adverse events. The process can take 10–15 years and command vast research and development resources costing over $1 billion. The success rates for new drug approvals in the United States are < 15%, and investment costs often cannot be recouped. With the increasing availability of large public datasets (big data) and computational capabilities, data science is quickly becoming a key component of the drug discovery pipeline. One such computational method, large-scale molecular modeling, is critical in the preclinical hit and lead identification process. Molecular modeling involves the study of the chemical structure of a drug and how it interacts with a potential disease-relevant target, as well as predicting its ADMET properties. The scope of molecular modeling is wide and complex. Here we specifically discuss docking, a tool commonly employed for studying drug-target interactions. Docking allows for the systematic exploration of how a drug interacts at a protein binding site and allows for the rank-ordering of drug libraries for prioritization in subsequent studies. This process can be efficiently used to virtually screen libraries containing over millions of compounds.

Original languageEnglish (US)
Pages (from-to)2400-2408.e1
JournalJournal of Investigative Dermatology
Volume139
Issue number12
DOIs
StatePublished - Dec 2019

Fingerprint

Dermatology
Drug Discovery
Computer Simulation
Research Design
Molecular modeling
Pharmaceutical Preparations
Drug Approval
Drug Interactions
Protein Binding
Libraries
Binding Sites
Clinical Trials
Computational methods
Costs and Cost Analysis
Toxicity
Pipelines
Research
Availability

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Cite this

Research Techniques Made Simple : Molecular Docking in Dermatology - A Foray into In Silico Drug Discovery. / Issa, Naiem T.; Badiavas, Evangelos V.; Schürer, Stephan.

In: Journal of Investigative Dermatology, Vol. 139, No. 12, 12.2019, p. 2400-2408.e1.

Research output: Contribution to journalShort survey

@article{7a0fade82d5b47c9872dac2ea72938db,
title = "Research Techniques Made Simple: Molecular Docking in Dermatology - A Foray into In Silico Drug Discovery",
abstract = "Drug discovery is a complex process with many potential pitfalls. To go to market, a drug must undergo extensive preclinical optimization followed by clinical trials to establish its efficacy and minimize toxicity and adverse events. The process can take 10–15 years and command vast research and development resources costing over $1 billion. The success rates for new drug approvals in the United States are < 15{\%}, and investment costs often cannot be recouped. With the increasing availability of large public datasets (big data) and computational capabilities, data science is quickly becoming a key component of the drug discovery pipeline. One such computational method, large-scale molecular modeling, is critical in the preclinical hit and lead identification process. Molecular modeling involves the study of the chemical structure of a drug and how it interacts with a potential disease-relevant target, as well as predicting its ADMET properties. The scope of molecular modeling is wide and complex. Here we specifically discuss docking, a tool commonly employed for studying drug-target interactions. Docking allows for the systematic exploration of how a drug interacts at a protein binding site and allows for the rank-ordering of drug libraries for prioritization in subsequent studies. This process can be efficiently used to virtually screen libraries containing over millions of compounds.",
author = "Issa, {Naiem T.} and Badiavas, {Evangelos V.} and Stephan Sch{\"u}rer",
year = "2019",
month = "12",
doi = "10.1016/j.jid.2019.06.129",
language = "English (US)",
volume = "139",
pages = "2400--2408.e1",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Research Techniques Made Simple

T2 - Molecular Docking in Dermatology - A Foray into In Silico Drug Discovery

AU - Issa, Naiem T.

AU - Badiavas, Evangelos V.

AU - Schürer, Stephan

PY - 2019/12

Y1 - 2019/12

N2 - Drug discovery is a complex process with many potential pitfalls. To go to market, a drug must undergo extensive preclinical optimization followed by clinical trials to establish its efficacy and minimize toxicity and adverse events. The process can take 10–15 years and command vast research and development resources costing over $1 billion. The success rates for new drug approvals in the United States are < 15%, and investment costs often cannot be recouped. With the increasing availability of large public datasets (big data) and computational capabilities, data science is quickly becoming a key component of the drug discovery pipeline. One such computational method, large-scale molecular modeling, is critical in the preclinical hit and lead identification process. Molecular modeling involves the study of the chemical structure of a drug and how it interacts with a potential disease-relevant target, as well as predicting its ADMET properties. The scope of molecular modeling is wide and complex. Here we specifically discuss docking, a tool commonly employed for studying drug-target interactions. Docking allows for the systematic exploration of how a drug interacts at a protein binding site and allows for the rank-ordering of drug libraries for prioritization in subsequent studies. This process can be efficiently used to virtually screen libraries containing over millions of compounds.

AB - Drug discovery is a complex process with many potential pitfalls. To go to market, a drug must undergo extensive preclinical optimization followed by clinical trials to establish its efficacy and minimize toxicity and adverse events. The process can take 10–15 years and command vast research and development resources costing over $1 billion. The success rates for new drug approvals in the United States are < 15%, and investment costs often cannot be recouped. With the increasing availability of large public datasets (big data) and computational capabilities, data science is quickly becoming a key component of the drug discovery pipeline. One such computational method, large-scale molecular modeling, is critical in the preclinical hit and lead identification process. Molecular modeling involves the study of the chemical structure of a drug and how it interacts with a potential disease-relevant target, as well as predicting its ADMET properties. The scope of molecular modeling is wide and complex. Here we specifically discuss docking, a tool commonly employed for studying drug-target interactions. Docking allows for the systematic exploration of how a drug interacts at a protein binding site and allows for the rank-ordering of drug libraries for prioritization in subsequent studies. This process can be efficiently used to virtually screen libraries containing over millions of compounds.

UR - http://www.scopus.com/inward/record.url?scp=85074530224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074530224&partnerID=8YFLogxK

U2 - 10.1016/j.jid.2019.06.129

DO - 10.1016/j.jid.2019.06.129

M3 - Short survey

AN - SCOPUS:85074530224

VL - 139

SP - 2400-2408.e1

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 12

ER -